Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

Camphor [76-22-2]

Imprimer

Référence HY-N0808-500g

Conditionnement : 500g

Marque : MedChemExpress

Demander plus d'informations

Description

Camphor ((±)-Camphor) is a topical anti-infective and anti-pruritic and internally as a stimulant and carminative. However, Camphor is poisonous when ingested. Antiviral, antitussive, and anticancer activities^[1]. Camphor is a TRPV3 agonist^[2].

IC₅₀ & Target

TRPV3

Cellular Effect

Cell Line	Type	Value	Description	References
MDCK	EC₅₀	1644.7 μM Compound: 1	Antiviral activity against Influenza virus A/California/07/09 (H1N1)pdm09 infected in MDCK cells assessed as inhibition of viral replication incubated for 1 hr prior to viral infection measured after 48 hrs by hemagglutination reaction Antiviral activity against Influenza virus A/California/07/09 (H1N1)pdm09 infected in MDCK cells assessed as inhibition of viral replication incubated for 1 hr prior to viral infection measured after 48 hrs by hemagglutination reaction	[PMID: 23993669]
MDCK	ED₅₀	1644.7 μM Compound: 1	Antiviral activity against rimantidine, amantadine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication by hemagglutinin titer assay Antiviral activity against rimantidine, amantadine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication by hemagglutinin titer assay	[PMID: 24631360]

In Vitro

Camphor induces fibroblast proliferation through the PI3K/AKT and ERK signaling pathways^[3].
The MTT assay results show that 32.5, 65, 130, and 260 μM Camphor increase fibroblast viability to 108.9±6.6%, 118.6±2.8%, 127.7±4.2%, and 131.6±7.2%, respectively, compared to 0 μM Camphor treatment^[3].
Camphor (0-260 μM) treatment for 24 hours increases the generation of ROS by up to 17.97% compared to 5.04% in the no-treatment control^[3]. Camphor (0-260 μM, 24 hours) induces the phosphorylation of PI3K, AKT, ERK, and 4EBP1 in a dose- and time-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	Primary dermal fibroblast cells
Concentration:	0-260 μM
Incubation Time:	24 hours
Result:	32.5, 65, 130, and 260 μM increased fibroblast viability to 108.9±6.6%, 118.6±2.8%, 127.7±4.2%, and 131.6±7.2%, respectively, compared to 0 μM treatment.

Western Blot Analysis^[3]

Cell Line:	Primary dermal fibroblast cells
Concentration:	0-260 μM
Incubation Time:	24 hours
Result:	Induced the phosphorylation of PI3K, AKT, ERK, and 4EBP1, a repressor of mRNA translation and mTOR substrate, in a dose- and time-dependent manner.

Essai clinique

Masse moléculaire

152.24

Formule

C₁₀H₁₆O

CAS No.

76-22-2

Appearance

Solid

Color

White to off-white

SMILES

O=C1C(C2(C)C)(C)CCC2C1

Structure Classification

Initial Source

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (656.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 3.33 mg/mL (21.87 mM; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.5686 mL	32.8429 mL	65.6858 mL
5 mM	1.3137 mL	6.5686 mL	13.1372 mL
10 mM	0.6569 mL	3.2843 mL	6.5686 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 3.33 mg/mL (21.87 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Pureté et documentation

Purity: 98.0%

Fiche technique (280 KB) SDS (933 KB)

COA (255 KB) HNMR (238 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Chen W, et al. Camphor--a fumigant during the Black Death and a coveted fragrant wood in ancient Egypt and Babylon--a review. Molecules. 2013 May 10;18(5):5434-54. [Content Brief]

[2]. Billen B, et al. Different ligands of the TRPV3 cation channel cause distinct conformational changes as revealedby intrinsic tryptophan fluorescence quenching. J Biol Chem. 2015 May 15;290(20):12964-74. [Content Brief]

[3]. Tran TA, et al. Camphor Induces Proliferative and Anti-senescence Activities in Human Primary Dermal Fibroblasts and Inhibits UV-Induced Wrinkle Formation in Mouse Skin. Phytother Res. 2015 Dec;29(12):1917-25. [Content Brief]

Camphor [76-22-2]

Référence HY-N0808-500g

Marque : MedChemExpress

Camphor Related Antibodies